الصفحة الرئيسية>>Glabrescione B

Glabrescione B

رقم الكتالوجGC62043

Glabrescione B هو أول مركب يربط Hedgehog (Hh) المغير Gli1يضعف Glabrescione B نشاطه عن طريق التدخل في تفاعل Gli1-DNAيمنع Glabrescione B نمو الخلايا السرطانية المعتمدة على القنفذ ، والقدرة على التجديد الذاتي ، واستنساخ الخلايا الجذعية المشتقة من الورم

Products are for research use only. Not for human use. We do not sell to patients.

Glabrescione B التركيب الكيميائي

Cas No.: 65893-94-9

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
445٫50
متوفر
5 mg
405٫00
متوفر
10 mg
720٫00
متوفر
25 mg
1485٫00
متوفر
50 mg
2025٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Glabrescione B is the first compound that binds the Hedgehog (Hh) modulator Gli1. Glabrescione B impairs its activity by interfering with Gli1-DNA interaction. Glabrescione B inhibits the growth of Hedgehog-dependent tumor cells, the self-renewal ability, and clonogenicity of tumor-derived stem cells[1][2].

Glabrescione B (5 μM; 24-72 hours) inhibits the growth of Gli-dependent basal cell carcinoma[2].Glabrescione B (1-10 μM; 24-48 hours) decreases Gli1 mRNA expression levels[2].

[1]. Ingallina C, et al. Polymeric glabrescione B nanocapsules for passive targeting of Hedgehog-dependent tumor therapy in vitro. Nanomedicine (Lond). 2017;12(7):711-728.
[2]. Infante P, et al. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J. 2015;34(2):200-217.

مراجعات

Review for Glabrescione B

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Glabrescione B

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.